ID   SU2
AC   CVCL_RQ44
SY   SU-2
DR   Wikidata; Q54970756
RX   PubMed=18940013;
RX   PubMed=22360855;
CC   Group: Cancer stem cell line.
CC   Population: Chinese.
CC   Omics: Array-based CGH.
CC   Derived from site: In situ; Brain, right temporal lobe; UBERON=UBERON_0002809.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RQ43 ! SU1
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 6
//
RX   PubMed=18940013; DOI=10.1186/1471-2407-8-304;
RA   Huang Q., Zhang Q.-B., Dong J., Wu Y.-Y., Shen Y.-T., Zhao Y.-D.,
RA   Zhu Y.-D., Diao Y., Wang A.-D., Lan Q.;
RT   "Glioma stem cells are more aggressive in recurrent tumors with
RT   malignant progression than in the primary tumor, and both can be
RT   maintained long-term in vitro.";
RL   BMC Cancer 8:304.1-304.11(2008).
//
RX   PubMed=22360855; DOI=10.5732/cjc.011.10336;
RA   Wan Y., Fei X.-F., Wang Z.-M., Jiang D.-Y., Chen H.-C., Yang J., Shi L.,
RA   Huang Q.;
RT   "Expression of miR-125b in the new, highly invasive glioma stem cell
RT   and progenitor cell line SU3.";
RL   Chin. J. Cancer 31:207-214(2012).
//